Condition
    Moderate Evidence
    Effectiveness 3/5

    Vitamin E for Non-Alcoholic Steatohepatitis

    Vitamin E is the only supplement with guideline recognition in steatohepatitis, based on histological improvement in biopsy-proven disease.

    Overview

    Vitamin E is one of the few supplements with a genuine randomised trial behind it in liver disease. In PIVENS, published in the New England Journal of Medicine, 800 IU of vitamin E daily achieved the primary histological improvement endpoint in 43 percent of patients compared with 19 percent on placebo.
    Two caveats define how that result should be used. Steatosis and lobular inflammation improved, but fibrosis - the feature that actually predicts long-term liver outcomes - did not. And the trial enrolled adults with biopsy-confirmed steatohepatitis who did not have diabetes, so it does not speak for everyone with a fatty liver on ultrasound. This is therefore a clinician-supervised intervention for a diagnosed condition, not a general liver supplement.

    Weight loss remains the primary treatment

    A 7-10 percent reduction in body weight improves steatohepatitis histology more reliably than any supplement. Vitamin E is an adjunct to that, not a replacement.

    How It Works

    Steatohepatitis progresses when fat accumulation in hepatocytes generates oxidative stress faster than the cell can neutralise it. Lipid peroxidation damages membranes and mitochondria, and the resulting injury signals recruit inflammatory cells.
    Alpha-tocopherol is a lipid-soluble chain-breaking antioxidant that sits inside those membranes and terminates peroxidation reactions. That is a direct match for the proposed driver of hepatocellular injury, which is why the histological features tied to inflammation responded in trial. It also explains the ceiling. Antioxidant defence does nothing to reverse collagen already laid down by activated stellate cells, which is consistent with the absence of a fibrosis benefit.

    Dosing & Protocol

    The dose used in PIVENS is specific and unusually high for a vitamin E supplement, which is precisely why it belongs under medical supervision rather than self-selection.
    ContextDoseFormTiming
    PIVENS trial protocol800 IU dailyNatural RRR-alpha-tocopherolDaily with a fat-containing meal
    General antioxidant intake15 mg (about 22 IU) dailyDiet or standard multivitaminDaily
    Trial duration96 weeks-Continuous, clinician-monitored
    Review point-Liver enzymes and clinical reviewEvery 3-6 months

    800 IU is a prescribed-level dose

    This is roughly forty times typical dietary intake and carries risks that ordinary supplement doses do not. Do not start it without a hepatologist or physician directing the decision.

    Evidence

    The linked evidence is PIVENS, a 2010 randomised controlled trial in 247 adults comparing pioglitazone, vitamin E and placebo in non-diabetic adults with biopsy-proven steatohepatitis.

    Studies linked to this pairing.

    Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis (PIVENS)

    Score: 9/10
    2010
    rct
    n=247

    Sanyal AJ, Chalasani N, Kowdley KV +3 more

    Vitamin E was superior to placebo for improving histological features of nonalcoholic steatohepatitis.

    View source
    Vitamin E met the primary histological endpoint in 43 percent versus 19 percent on placebo, with reductions in steatosis and lobular inflammation. Fibrosis scores did not improve. The main boundaries on generalising the result are the exclusion of people with diabetes and of those with cirrhosis, the requirement for biopsy confirmation, and the fact that histology is a surrogate for the outcomes patients care about - liver failure, transplant and mortality - which the trial was not sized to measure.

    Safety

    High-dose vitamin E is not benign. Meta-analyses of doses at or above 400 IU daily have raised concerns about all-cause mortality, and the SELECT trial reported an increased incidence of prostate cancer among men taking 400 IU daily.

    Bleeding risk rises at these doses

    Vitamin E has antiplatelet activity. Stop it before planned surgery as directed by your surgeon, and do not combine with anticoagulants without medical oversight.

    People with diabetes, cirrhosis or a history of haemorrhagic stroke sit outside the trial population and outside the balance of risk it established. Men should weigh the prostate cancer signal explicitly with their clinician before starting long-term high-dose therapy.

    Interactions & Conflicts

    The clinically important conflicts at 800 IU centre on bleeding and on absorption of other fat-soluble nutrients.
    Interacts withSeverityMechanismAction
    Warfarin and DOACs
    high
    		Additive antiplatelet effect and vitamin K antagonismDo not combine without medical supervision
    Aspirin or clopidogrel
    moderate
    		Additive bleeding riskDiscuss with your prescriber before starting
    Fish oil at high dose
    low
    		Further platelet effectAvoid stacking around surgery or dental work
    Orlistat and bile acid sequestrants
    low
    		Reduced fat-soluble vitamin absorptionSeparate doses by several hours

    References

    The citation below is the study currently linked to this pairing in our library.

    Frequently Asked Questions

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.